HGH (Somatropin) vs MGF (Mechano Growth Factor)
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Somatropin, Human Growth Hormone
Human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. It is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. Almost everything you read about HGH for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used.
Also: Mechano Growth Factor, IGF-1Ec
MGF is the name given to a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) that muscle switches on after loading or damage. The "MGF" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the E-domain, sequence YQPPSTNKNTKSQRRKGSTFEEHK), often with a modified C-terminus. It got famous through early lab work from Geoffrey Goldspink's group suggesting it kicks muscle stem cells into action. The honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials.
Key Comparison Insights
- HGH (Somatropin) is FDA approved, while MGF (Mechano Growth Factor) remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- HGH (Somatropin) has stronger research evidence (FDA Approved) compared to MGF (Mechano Growth Factor) (Preclinical).
Detailed Comparison
| Attribute | HGH (Somatropin) | MGF (Mechano Growth Factor) |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | HGH binds the growth hormone receptor, mostly in the liver, which triggers IGF-1 release. IGF-1 does much of the work people associate with growth hormone: it drives cell growth, protein synthesis and cartilage growth. HGH itself acts directly on fat tissue, encouraging lipolysis, and it opposes insulin, which is why higher doses push blood sugar up and can create insulin resistance over time. The direct-versus-IGF-1 split matters practically: effects on fat come quickly and are largely direct, while effects on muscle and connective tissue are slower and IGF-1 mediated. This is also why HGH and IGF-1 LR3 are not interchangeable despite being linked. | The idea goes like this. When muscle is stretched or injured, the IGF-1 gene is spliced differently, producing a version with a different C-terminal E-domain. Researchers proposed that this E-domain gets cut off and acts on its own, pushing satellite cells (muscle stem cells) to multiply before mature IGF-1 tells them to fuse and build new fibers. Several studies reported that the E-peptide works without the classic IGF-1 receptor, and in heart cells it was reported to enter the cell, travel to the nucleus, and block the mitochondrial apoptosis pathway. The problem is that nobody has identified MGF's receptor, a 2010 Endocrinology review pointed out that no matching peptide has ever been isolated from cells, tissue or blood, and a 2014 study from Novartis and another drug company could not reproduce the core muscle-cell effects. So the mechanism is a hypothesis built on synthetic-peptide experiments, not established biology. |
| Common Dosing | 0.15-0.3 mg daily (clinical) or 2-4 IU daily (community) Once daily, typically evening | No established human dose Not established |
| Administration | Subcutaneous injection, usually daily, commonly in the evening to mimic natural nocturnal release | Local injection or infusion into tissue in animal studies; research-market products are injected |
| Typical Duration | Clinical use is ongoing and monitored. Community cycles are typically reported as 3-6 months. | Single treatments or days to weeks in animal models; no human protocols exist |
| Best Time to Take | Evening, before bed | Not established |
Possible Side Effects May vary by individual |
|
|
| Research Summary | For diagnosed growth hormone deficiency the evidence is solid and decades deep: recombinant HGH restores body composition, bone density and quality of life in adults with genuine deficiency, and it is approved for that. For everyone else the picture is far weaker. The famous Rudman study in the New England Journal of Medicine in 1990 gave HGH to 12 older men for six months and reported gains in lean mass and reductions in fat, and that single small trial launched an entire anti-aging industry. It had no functional strength or performance endpoints, it was not designed to assess safety, and Rudman maintained until his death in 1994 that it carried no anti-aging implications. NEJM published an editorial in 2003 criticizing the industry that had grown up around citing it. Subsequent reviews of HGH in healthy older adults have found modest body composition changes alongside frequent side effects, with no demonstrated benefit to strength, function or longevity. Long-term supraphysiologic use carries real risks including insulin resistance and, at sustained high doses, acromegaly-like changes. | The supportive work is real but almost all in cells and animals. Yang and Goldspink (FEBS Letters, 2002) reported that the E-domain increased myoblast proliferation and delayed differentiation. Kandalla and colleagues (2011) reported it extended the proliferative lifespan of human muscle precursor cells from young donors, but not from old donors. In sheep with induced heart attacks, local MGF E-domain preserved cardiac function and cut compromised heart muscle by about 35% (Carpenter, 2008), and similar heart-protection results came from mouse studies. A gerbil stroke model showed strong neuroprotection (Dluzniewska, 2005). Then the counterpoint: Fornaro and colleagues (Am J Physiol Endocrinol Metab, 2014) tested MGF up to 500 ng/ml on mouse and human muscle cells and primary muscle stem cells and saw no effect on proliferation or differentiation, while real IGF-1 worked fine. An accompanying editorial was titled "The Fall of Mechanogrowth Factor?". In humans, the only solid data is about gene expression: heavy leg extensions raised MGF mRNA in young men but not in older men (Hameed, 2003). There are no human dosing studies and no clinical trials. One more flag: MGF E-peptide drove growth of prostate cancer cells in a lab study, and MGF was found overexpressed in prostate cancer tissue (Armakolas, 2010). |
Frequently Asked Questions: HGH (Somatropin) vs MGF (Mechano Growth Factor)
What is the difference between HGH (Somatropin) and MGF (Mechano Growth Factor)?
HGH (Somatropin) is a growth hormone peptide that human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. it is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. almost everything you read about hgh for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used. MGF (Mechano Growth Factor) is a growth hormone peptide that mgf is the name given to a splice variant of the igf-1 gene (igf-1ec in humans, igf-1eb in rodents) that muscle switches on after loading or damage. the "mgf" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the e-domain, sequence yqppstnkntksqrrkgstfeehk), often with a modified c-terminus. it got famous through early lab work from geoffrey goldspink's group suggesting it kicks muscle stem cells into action. the honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, HGH (Somatropin) or MGF (Mechano Growth Factor)?
Neither is universally "better" - the choice depends on your specific goals. HGH (Somatropin) is typically used for growth hormone purposes, while MGF (Mechano Growth Factor) is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can HGH (Somatropin) and MGF (Mechano Growth Factor) be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using HGH (Somatropin) and MGF (Mechano Growth Factor) together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.